Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Acquisitions (2022 - 2025)

Maravai Lifesciences Holdings (MRVI) has 3 years of Acquisitions data on record, last reported at $362000.0 in Q2 2025.

  • For Q2 2025, Acquisitions changed N/A year-over-year to $362000.0; the TTM value through Dec 2025 reached $19.0 million, changed N/A, while the annual FY2025 figure was $19.0 million, N/A changed from the prior year.
  • Acquisitions reached $362000.0 in Q2 2025 per MRVI's latest filing, down from $18.6 million in the prior quarter.
  • Across five years, Acquisitions topped out at $238.8 million in Q1 2022 and bottomed at -$109000.0 in Q2 2023.
  • Average Acquisitions over 3 years is $54.6 million, with a median of $9.5 million recorded in 2025.
  • The widest YoY moves for Acquisitions: up 70.8% in 2023, down 70.8% in 2023.
  • A 3-year view of Acquisitions shows it stood at $133000.0 in 2022, then tumbled by 181.95% to -$109000.0 in 2023, then skyrocketed by 432.11% to $362000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $362000.0 in Q2 2025, $18.6 million in Q1 2025, and -$109000.0 in Q2 2023.